loader image
Monday, October 20, 2025
92.6 F
McAllen
- Advertisement -

Safe to Give Clot-busting Drug to Stroke Patients Who Took Blood Thinners

Translate to Spanish or other 102 languages!

Stroke patients on long-term blood thinners who were given the clot-busting drug alteplase enjoyed better recoveries than those who did not receive the drug and had no increased risk of bleeding, a new study led by UTSW researchers shows. Image for illustration purposes.
Stroke patients on long-term blood thinners who were given the clot-busting drug alteplase enjoyed better recoveries than those who did not receive the drug and had no increased risk of bleeding, a new study led by UTSW researchers shows. Image for illustration purposes.

Mega Doctor News

- Advertisement -

by UT Southwestern Medical Center

Newswise — Stroke patients on long-term blood thinners who were given the clot-busting drug alteplase enjoyed better recoveries than those who did not receive the drug and had no increased risk of bleeding, a new study led by UTSW researchers shows. The results run counter to the common practice of withholding the clot-busting drug to these patients due to concerns over complications from bleeding.  

Many patients at risk of heart attack or stroke from nonvalvular atrial fibrillation take widely used blood thinners known as non-vitamin K antagonist oral anticoagulants (NOACs) to reduce the risk of stroke. But clinicians have been hesitant to give alteplase, the only approved medical therapy for acute ischemic stroke, to patients on blood thinners who have a stroke, believing it would cause excess bleeding such as a brain hemorrhage.

- Advertisement -

Published in JAMA, the study of more than 160,000 patients – the largest of its kind – found 2,207 patients who were taking NOACs prior to having a stroke and were treated with alteplase. It found no evidence that the patients were at risk of excess bleeding. Instead, they were able to return home free of disabilities and able to ambulate and function independently.

“The real risk is in not treating patients – they would otherwise be left with lifelong disability from their stroke,” said Ying Xian, M.D., Ph.D., an author of the study, Associate Professor of Neurology and Population and Data Sciences, and Section Head of Research, Stroke and Cerebrovascular Diseases.

Approved in early 2010s, NOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban made up nearly 80% of new blood thinner prescriptions in 2017, and that number is believed to be higher now, Dr. Xian said. A clinical trial of alteplase in NOAC patients is unlikely, so Dr. Xian and his colleagues studied data from 163,083 patients across the United States in the American Heart Association’s Stroke Registry.

UT Southwestern is certified as an Advanced Comprehensive Stroke Center by The Joint Commission and the American Heart Association/American Stroke Association. UT Southwestern is ranked as high performing for stroke care by U.S. News and World Report, where it is ranked No.19 in the nation for Neurology and Neurosurgery.

- Advertisement -

Other UT Southwestern researchers who contributed to the study are DaiWai Olson, Ph.D., R.N., and Eric Peterson, M.D., M.P.H., Vice Provost and Senior Associate Dean for Clinical Research and Professor of Internal Medicine.

The Get With The Guidelines-Stroke (GWTG-Stroke) program is led by the American Heart Association (AHA) and the American Stroke Association (ASA). The Addressing Real-World Anticoagulant Management Issues in Stroke (ARAMIS) registry is a multicenter cohort study of acute stroke patients which is built upon the existing infrastructure of the AHA/ASA GWTG-Stroke program. Both the GWTG-Stroke program and ARAMIS study have multiple corporate sponsors as identified in the study write-up. Financial disclosures for the authors are included in the manuscript.

Dr. Peterson holds the Adelyn and Edmund M. Hoffman Distinguished Chair in Medical Science.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Hosting Webinar on Lung Health, Oct. 21st

Mega Doctor News By supplying oxygen to the body and filtering harmful substances like carbon dioxide, the lungs...

STHS to Provide Amputation Prevention Education, Oct. 26th

Mega Doctor News Despite medical advancements like regenerative wound care, minimally invasive surgical...

Alzheimer’s Association Urges Texans to Vote ‘Yes on 14’ and Fight Dementia

Early voting begins October 20th, giving Texans their first chance to support making the state a national leader in dementia prevention and research. Texas Proposition 14, if approved, would fund the Dementia Prevention and Research Institute of Texas (DPRIT). A “Yes” vote on Prop 14 accelerates progress toward prevention, treatments and a cure, offering hope to Texas families – right here at home.

Dr. Ali Kilic: Advancing Patient-Centered Reconstructive Surgery in the Rio Grande Valley

At the 2025 DHR Health Fashion Show & Gala Honoring Heroic Patients, held on October 15 at the Edinburg Conference Center at Renaissance, Dr. Ali Kilic, Plastic and Reconstructive Surgeon and Hand Surgeon at DHR Health, was recognized for his commitment to patient-centered reconstructive care and his role in empowering women to reclaim their confidence after breast cancer treatment. The event, themed “A Celebration of Strength, Courage, and Empowerment,” celebrated breast cancer survivors who have undergone reconstruction and honored the physicians who help them heal.
- Advertisement -
×